tiprankstipranks
Trending News
More News >

Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder

Story Highlights
Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder

Confident Investing Starts Here:

Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.

Tryptamine Therapeutics has established a framework for a world-first clinical trial to treat Binge Eating Disorder (BED) using TRP-8803, in collaboration with Swinburne University. The trial aims to assess the safety and efficacy of TRP-8803, administered with psychotherapy, in BED patients, potentially impacting the treatment landscape for this prevalent disorder in the US and Australia.

More about Tryptamine Therapeutics

Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing TRP-8803, a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits.

Average Trading Volume: 1,474,349

Technical Sentiment Signal: Sell

Current Market Cap: A$46.05M

Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App